|
Physiomics PLC - Abingdon, Oxfordshire-based mathematical modelling and data science for new medicines - Wins new contract from ‘an existing, large client’, worth £186,000. According to the agreement, the client will use Physiomics’ proprietary Virtual Tumour platform to model its targeted oncology agents in combination with other modalities, in order to help inform dose and scheduling decisions. As a result, Physiomics will be entering the next financial year - ending June 30, 2025 - with committed revenue of over £500,000. Chief Executive Officer Peter Sargent says: ‘After many months of discussion and negotiation with the client, I’m delighted that we can now start this substantial project. This win reflects the significant experience and expertise the Physiomics team has built up over the years, in particular around more complex modelling of combination therapies.’ Current stock price: 1.32 pence 12-month change: down 35% Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
